TAFAMIDIS MEGLUMINE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Foldrx Pharms	VYNDAQEL	tafamidis meglumine	CAPSULE;ORAL	211996	NDA	Pfizer Laboratories Div Pfizer Inc	0069-1975-40	4 CARTON in 1 CARTON (0069-1975-40) / 30 BLISTER PACK in 1 CARTON / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0069-1975-12)	2019-05-16
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

EXECUTIVE SUMMARY

This report analyzes the supply chain for tafamidis meglumine, the active pharmaceutical ingredient (API) in Vyndaqel and Vyndamax, treatments for transthyretin amyloid cardiomyopathy (ATTR-CM) and transthyretin amyloid polyneuropathy (ATTR-PN). Key suppliers are identified, patent landscapes are reviewed, and regulatory considerations are highlighted. The analysis focuses on manufacturing capabilities, geographic distribution of production, and potential risks to supply continuity.

TAFAMIDIS MEGLUMINE: API MANUFACTURING AND KEY SUPPLIERS

Tafamidis meglumine is a complex small molecule API requiring specialized synthesis and manufacturing capabilities. The production process involves multiple chemical steps, purification, and salt formation. The primary manufacturer and supplier of tafamidis meglumine for Pfizer's branded products is Pfizer itself, through its internal manufacturing facilities and potentially contract manufacturing organizations (CMOs) under strict quality agreements.

The proprietary nature of the synthesis route and the stringent quality control required for pharmaceutical-grade API production limit the number of readily available commercial suppliers. Companies seeking to enter the tafamidis meglumine market, particularly for generic development, would face significant hurdles in developing non-infringing synthetic pathways and establishing validated manufacturing processes compliant with Good Manufacturing Practices (GMP).

API Synthesis and Manufacturing Considerations

Chemical Complexity: The synthesis of tafamidis meglumine involves multiple chiral centers and specific functional groups, necessitating precise reaction control and purification techniques.
Regulatory Compliance: All manufacturing sites and processes must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Quality Control: Rigorous analytical testing is required at each stage of production to ensure purity, potency, and absence of impurities. This includes methods like High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR).
Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial-scale production presents engineering and chemical challenges that require extensive process development and validation.
Supply Chain Security: Ensuring a secure and reliable supply chain for raw materials and intermediates is critical. This involves qualifying multiple suppliers for key starting materials and reagents.

Potential API Manufacturers and CMOs

While Pfizer likely maintains significant in-house manufacturing, companies specializing in complex API synthesis and custom manufacturing are potential partners for any entity looking to produce tafamidis meglumine, especially for generic formulations. These include:

Lonza: A global CDMO with extensive experience in complex small molecule API manufacturing and scale-up.
Catalent: Offers integrated drug development and manufacturing services, including API production.
WuXi AppTec: Provides a broad range of R&D and manufacturing services for the pharmaceutical industry.
Granules India: Known for its expertise in API manufacturing and its strong regulatory track record.
Divi's Laboratories: Another established Indian API manufacturer with a global presence.

It is important to note that the specific CMOs engaged by Pfizer, if any, are typically not publicly disclosed due to confidentiality agreements. Any generic manufacturer would need to independently establish its own supply chain, which may involve a different set of CMOs.

PATENT LANDSCAPE AND INTELLECTUAL PROPERTY

The intellectual property surrounding tafamidis meglumine is a critical factor influencing market entry and competition. Pfizer holds a portfolio of patents covering the compound itself, its formulations, methods of use, and manufacturing processes.

Key Patents and Expiry Dates

The primary patent protecting the tafamidis compound itself is U.S. Patent No. 7,951,990, which was granted on May 31, 2011. This patent, and its equivalents in other jurisdictions, is crucial.

U.S. Patent No. 7,951,990: "Dihydropyridine derivatives and their use" (Covers tafamidis compound).
- Original Expiry: May 31, 2028 (after 20-year term from filing, with potential for Patent Term Extension - PTE).
- Actual Expiry (with PTE): U.S. Patent Term Extension (PTE) typically grants an additional period to compensate for regulatory review delays. For tafamidis, the earliest the compound patent can expire is likely in 2030 or later, depending on the specific PTE granted and any further extensions or challenges. This is a crucial date for generic entry.

Pfizer also holds patents related to specific formulations, methods of administration, and indications.

Formulation Patents: These patents cover specific crystalline forms, salts, and excipient combinations that enhance stability, bioavailability, or ease of administration. For example, patents might cover amorphous forms or specific polymorphs.
Method of Use Patents: These patents protect the use of tafamidis for treating specific conditions, such as ATTR-CM and ATTR-PN. These can extend market exclusivity beyond the compound patent expiry. For instance, U.S. Patent No. 10,130,730 (and its continuations) relates to methods of treating ATTR-CM. The expiry of these method-of-use patents can significantly impact the market for new treatments or generic alternatives.
Manufacturing Process Patents: While often more difficult to litigate, process patents can also provide a layer of protection.

Generic Competition and Patent Litigation

Generic manufacturers typically aim to enter the market upon the expiry of key composition-of-matter patents. However, the process is often complex:

ANDA Filing: Generic companies file an Abbreviated New Drug Application (ANDA) with the FDA.
Paragraph IV Certification: The ANDA applicant must certify that the relevant patents listed in the Orange Book are either invalid, unenforceable, or will not be infringed by the generic product. This often triggers patent litigation.
Patent Litigation: Pfizer will likely vigorously defend its patents against ANDA filers. Litigation can involve challenges to patent validity, inventorship, and infringement claims. The outcome of these legal battles determines when generic products can be launched.

Example of Patent Litigation Impact: The U.S. District Court for the District of Delaware is a common venue for pharmaceutical patent litigation. The specific outcomes of any litigation against Pfizer's tafamidis patents will directly dictate the timeline for generic market entry. The interplay between compound patents, formulation patents, and method-of-use patents creates a layered defense strategy by the innovator.

The U.S. Patent and Trademark Office (USPTO) and the FDA's Orange Book are key resources for identifying and tracking these patents.

REGULATORY LANDSCAPE AND MARKET AUTHORIZATIONS

The approval and sale of tafamidis meglumine-containing drugs are governed by stringent regulatory requirements worldwide.

Key Regulatory Agencies

U.S. Food and Drug Administration (FDA): Approved Vyndaqel and Vyndamax for ATTR-PN (2019) and ATTR-CM (2020). The FDA's Center for Drug Evaluation and Research (CDER) oversees these approvals.
European Medicines Agency (EMA): Approved Vyndaqel for ATTR-PN in 2011 and expanded its indication to ATTR-CM in 2019.
Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: Approved for ATTR-PN.
Other National Regulatory Bodies: Health Canada, Therapeutic Goods Administration (TGA) - Australia, etc.

Regulatory Hurdles for Generic Manufacturers

Generic manufacturers face significant regulatory hurdles:

Demonstration of Bioequivalence: A generic product must demonstrate bioequivalence to the reference listed drug (Vyndaqel/Vyndamax). This involves comparative pharmacokinetic studies.
API Quality and GMP Compliance: The API manufacturing site and process must be fully compliant with cGMP. This requires successful FDA/EMA inspections.
Drug Product Formulation: The generic product must be formulated to achieve similar release profiles and stability characteristics as the innovator product.
Labeling: The generic label must be the same as the innovator product, with the exception of information specific to the generic product (e.g., manufacturer, inactive ingredients).

Exclusivities

Beyond patent protection, regulatory exclusivities can also delay generic competition:

New Chemical Entity (NCE) Exclusivity: For tafamidis, this exclusivity has likely expired or is expiring soon, as it was approved years ago.
Orphan Drug Exclusivity (ODE): Tafamidis received orphan drug designation for ATTR-CM in both the U.S. and Europe. In the U.S., ODE grants 7 years of market exclusivity from the date of approval for the specific orphan indication. This exclusivity is critical and may extend beyond patent expiry for certain indications.
Pediatric exclusivity: If applicable, this can add 6 months to existing exclusivities.

GEOGRAPHIC DISTRIBUTION OF MANUFACTURING AND SUPPLY CHAIN RISKS

The geographic concentration of API and drug product manufacturing can introduce supply chain risks.

API Manufacturing Locations

While Pfizer's internal manufacturing sites and potential CMOs are proprietary, common locations for API production include:

North America: U.S. and Canada.
Europe: Ireland, Germany, Switzerland.
Asia: India, China.

The precise location of tafamidis meglumine API production by Pfizer is not publicly disclosed but is likely concentrated in facilities with advanced chemical synthesis capabilities and robust quality systems.

Drug Product Manufacturing Locations

Finished drug product manufacturing for Vyndaqel and Vyndamax could occur in various locations globally, including:

North America: U.S.
Europe: Belgium, Ireland.

Pfizer's global network of manufacturing facilities ensures flexibility and redundancy, but any disruption at a key site or a significant portion of its supply chain could impact availability.

Supply Chain Risks

Geopolitical Instability: Disruptions in regions with concentrated manufacturing can lead to shortages.
Natural Disasters: Earthquakes, floods, and other natural events can impact manufacturing sites and transportation routes.
Raw Material Sourcing: Reliance on specific suppliers for critical starting materials or reagents can create vulnerabilities. For complex APIs like tafamidis, even minor disruptions in the supply of a single key intermediate can halt production.
Regulatory Changes: Evolving GMP standards or unexpected regulatory actions against a manufacturing facility can disrupt supply.
Logistical Challenges: Shipping delays, port congestion, and transportation infrastructure issues can impact the timely delivery of API and finished product.
Single Source Dependencies: Over-reliance on a single CMO or a specific manufacturing process can be risky. Diversification of suppliers and manufacturing sites is crucial for risk mitigation.
Intellectual Property Disputes: Litigation related to patents can lead to injunctions that halt the production or sale of competing products, indirectly impacting the market dynamics and potentially the demand on innovator supply chains if generics are delayed.

KEY TAKEAWAYS

Pfizer is the primary manufacturer of tafamidis meglumine API for its branded products, with potential reliance on select, undisclosed CMOs.
The patent landscape for tafamidis meglumine is robust, with key compound patents extending into the early 2030s, augmented by formulation and method-of-use patents. Orphan Drug Exclusivity provides an additional layer of market protection.
Generic entry is contingent upon navigating these patents and regulatory exclusivities, likely commencing after 2030, pending the outcome of any patent litigation.
Manufacturing of tafamidis meglumine API requires specialized expertise and adherence to strict cGMP standards, limiting the number of potential generic manufacturers.
Supply chain risks include geopolitical factors, natural disasters, raw material sourcing vulnerabilities, and regulatory compliance issues, necessitating diversified manufacturing and robust quality management.

FAQS

What is the current primary source for tafamidis meglumine API? Pfizer is the primary manufacturer for its branded tafamidis meglumine products, Vyndaqel and Vyndamax.
When can generic versions of tafamidis meglumine be expected to enter the market? Generic entry is anticipated following the expiry of key patent protections, likely in the early to mid-2030s, contingent on the outcome of patent litigation.
Are there publicly listed contract manufacturing organizations (CMOs) that currently produce tafamidis meglumine API? Specific CMOs engaged by Pfizer for tafamidis meglumine API production are not publicly disclosed due to confidentiality agreements. Companies seeking to develop generic tafamidis meglumine would need to establish their own supply chains, potentially utilizing CMOs such as Lonza, Catalent, or WuXi AppTec.
What are the main regulatory hurdles for generic tafamidis meglumine manufacturers? Key hurdles include demonstrating bioequivalence to the reference product, achieving stringent cGMP compliance for API and drug product manufacturing, and securing necessary marketing authorizations from regulatory bodies like the FDA and EMA.
What are the primary supply chain risks associated with tafamidis meglumine? Primary risks include geopolitical instability impacting manufacturing hubs, natural disasters affecting production sites, reliance on specific raw material suppliers, potential regulatory changes, and logistical challenges in global transportation.

CITATIONS

[1] U.S. Patent No. 7,951,990. (2011). Dihydropyridine derivatives and their use. Retrieved from USPTO. [2] U.S. Patent No. 10,130,730. (2019). Methods of treating transthyretin amyloid cardiomyopathy. Retrieved from USPTO. [3] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA.gov. [4] European Medicines Agency. (n.d.). Vyndaqel Product Information. Retrieved from EMA.europa.eu.

Suppliers and packagers for generic pharmaceutical drug: TAFAMIDIS MEGLUMINE